Michael Untch
Response
Moebus V, Untch M, Kreienberg R, Hinke A, Runnebaum I, Nitz U, Kuhn W, Kurbacher C, Thomssen C, du Bois A, Lueck H, Huober J, Schneeweiss A, Jackisch C, AGO Breast Study Group. Response. J Natl Cancer Inst 2014; 106:djt452.
28.02.2014Response
28.02.2014J Natl Cancer Inst 2014; 106:djt452
Moebus Volker, Untch Michael, Kreienberg Rolf, Hinke Axel, Runnebaum Ingo B, Nitz Ulrike A, Kuhn Walther, Kurbacher Christian, Thomssen Christoph, du Bois Andreas, Lueck Hans-Joachim, Huober Jens, Schneeweiss Andreas, Jackisch Christian, AGO Breast Study Group
Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma
Loibl S, Denkert C, Hilfrich J, Konecny G, Fett W, Stickeler E, Harbeck N, Mehta K, Nekljudova V, von Minckwitz G, Huober J, Kümmel S, Volz C, Mau C, Blohmer J, Costa S, Eidtmann H, Fasching P, Gerber B, Hanusch C, Jackisch C, Untch M. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat 2014; 144:153-62.
07.02.2014Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma
07.02.2014Breast Cancer Res Treat 2014; 144:153-62
Loibl Sibylle, Denkert Carsten, Hilfrich Jörn, Konecny Gottfried E, Fett Werner, Stickeler Elmar, Harbeck Nadia, Mehta Keyur M, Nekljudova Valentina, von Minckwitz Gunter, Huober Jens, Kümmel Sherko, Volz Cristina, Mau Christine, Blohmer Jens-Uwe, Costa Serban D, Eidtmann Holger, Fasching Peter A, Gerber Bernd, Hanusch Claus, Jackisch Christian, Untch Michael
Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective
Harbeck N, Wuerstlein R, Welt A, Tesch H, Schneeweiss A, Scharl A, von Minckwitz G, Lück H, Huober J, Jackisch C, Hegewisch-Becker S, Decker T, Untch M, Marschner N, Thomssen C. Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective. Breast Care (Basel) 2014; 9:52-9.
01.02.2014Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective
01.02.2014Breast Care (Basel) 2014; 9:52-9
Harbeck Nadia, Wuerstlein Rachel, Welt Anja, Tesch Hans, Schneeweiss Andreas, Scharl Anton, von Minckwitz Gunter, Lück Hans-Joachim, Huober Jens, Jackisch Christian, Hegewisch-Becker Susanna, Decker Thomas, Untch Michael, Marschner Norbert, Thomssen Christoph
Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients
Hilvo M, Orešič M, Denkert C, von Minckwitz G, Huober J, Untch M, Sysi-Aho M, Seppänen-Laakso T, Nekljudova V, Hyötyläinen T, Gade S, Loibl S. Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer 2013; 134:1725-33.
08.10.2013Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients
08.10.2013Int J Cancer 2013; 134:1725-33
Hilvo Mika, Orešič Matej, Denkert Carsten, von Minckwitz Gunter, Huober Jens, Untch Michael, Sysi-Aho Marko, Seppänen-Laakso Tuulikki, Nekljudova Valentina, Hyötyläinen Tuulia, Gade Stephan, Loibl Sibylle
Response-guided neoadjuvant chemotherapy for breast cancer
von Minckwitz G, Mehta K, Zahm D, Untch M, Schneeweiss A, Paepke S, Kümmel S, Kaufmann M, Jackisch C, Huober J, Hilfrich J, Hanusch C, Gerber B, Eiermann W, Eidtmann H, Denkert C, Costa S, Blohmer J, Loibl S. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2013; 31:3623-30.
03.09.2013Response-guided neoadjuvant chemotherapy for breast cancer
03.09.2013J Clin Oncol 2013; 31:3623-30
von Minckwitz Gunter, Mehta Keyur, Zahm Dirk Michael, Untch Michael, Schneeweiss Andreas, Paepke Stefan, Kümmel Sherko, Kaufmann Manfred, Jackisch Christian, Huober Jens, Hilfrich Jörn, Hanusch Claus, Gerber Bernd, Eiermann Wolfgang, Eidtmann Holger, Denkert Carsten, Costa Serban Dan, Blohmer Jens Uwe, Loibl Sibylle
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
von Minckwitz G, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Lück H, Müller V, Kreienberg R, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel I, Elling D, Conrad B, Loibl S. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 2013; 31:3531-9.
26.08.2013German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
26.08.2013J Clin Oncol 2013; 31:3531-9
von Minckwitz Gunter, Bauerfeind Ingo, Clemens Michael, Schmidt Marcus, Noeding Stefanie, Forstbauer Helmut, Barinoff Jana, Belau Antje, Nekljudova Valentina, Harbeck Nadia, Lück Hans-Joachim, Müller Volkmar, Kreienberg Rolf, Möbus Volker, Schneeweiss Andreas, Huober Jens, Thomssen Christoph, Untch Michael, Jackisch Christian, Diel Ingo J, Elling Dirk, Conrad Bettina, Loibl Sibylle
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial
Moebus V, Untch M, Kreienberg R, Hinke A, Runnebaum I, Nitz U, Kuhn W, Kurbacher C, Thomssen C, du Bois A, Lueck H, Huober J, Schneeweiss A, Jackisch C, AGO Breast Study Group. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst 2013; 105:1018-26.
16.07.2013Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial
16.07.2013J Natl Cancer Inst 2013; 105:1018-26
Moebus Volker, Untch Michael, Kreienberg Rolf, Hinke Axel, Runnebaum Ingo B, Nitz Ulrike, Kuhn Walther, Kurbacher Christian, Thomssen Christoph, du Bois Andreas, Lueck Hans-Joachim, Huober Jens, Schneeweiss Andreas, Jackisch Christian, AGO Breast Study Group
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
Lück H, Schuster T, Wollschläger K, Untch M, Thomssen C, Eidtmann H, Stickeler E, Richter B, Hubalek M, Jackisch C, Stähler A, Beckmann M, Heilmann V, Huober J, Schrader I, Loibl S, du Bois A, von Minckwitz G. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Res Treat 2013; 139:779-87.
15.06.2013Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
15.06.2013Breast Cancer Res Treat 2013; 139:779-87
Lück Hans-Joachim, Schuster Tibor, Wollschläger Kerstin, Untch Michael, Thomssen Christoph, Eidtmann Holger, Stickeler Elmar, Richter Barbara, Hubalek Michael, Jackisch Christian, Stähler Ann, Beckmann Matthias, Heilmann Volker, Huober Jens, Schrader Iris, Loibl Sibylle, du Bois Andreas, von Minckwitz Gunter
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44)
Huober J, Kümmel S, Mau C, Jackisch C, Khandan F, Costa S, Krabisch P, Loibl S, Nekljudova V, Untch M, Höß C, Gerber B, Fasching P, Hanusch C, Rezai M, Eidtmann H, Kittel K, Hilfrich J, Schwedler K, Blohmer J, Tesch H, Minckwitz G. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). Eur J Cancer 2013; 49:2284-93.
27.03.2013Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44)
27.03.2013Eur J Cancer 2013; 49:2284-93
Huober Jens, Kümmel Sherko, Mau Christine, Jackisch Christian, Khandan Fariba, Costa Serban Dan, Krabisch Petra, Loibl Sibylle, Nekljudova Valentina, Untch Michael, Höß Cornelia, Gerber Bernd, Fasching Peter A, Hanusch Claus, Rezai Mahdi, Eidtmann Holger, Kittel Kornelia, Hilfrich Jörn, Schwedler Kathrin, Blohmer Jens-Uwe, Tesch Hans, Minckwitz Gunter von
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
Denkert C, von Minckwitz G, Tesch H, Hansmann M, Reinisch M, Engels K, Sinn B, Fasching P, Mehta K, Solbach C, Brase J, Darb-Esfahani S, Kronenwett R, Prinzler J, Loibl S, Huober J, Untch M. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res 2013; 15:R11.
07.02.2013HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
07.02.2013Breast Cancer Res 2013; 15:R11
Denkert Carsten, von Minckwitz Gunter, Tesch Hans, Hansmann Martin-Leo, Reinisch Mattea, Engels Knut, Sinn Bruno V, Fasching Peter A, Mehta Keyur, Solbach Christine, Brase Jan C, Darb-Esfahani Silvia, Kronenwett Ralf, Prinzler Judith, Loibl Sibylle, Huober Jens, Untch Michael
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
von Minckwitz G, Mehta K, Nekljudova V, Denkert C, Konecny G, Kaufmann M, Jackisch C, Huober J, Hilfrich J, Eiermann W, Gerber B, Fasching P, Eidtmann H, Costa S, Blohmer J, Untch M, Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30:1796-804.
16.04.2012Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
16.04.2012J Clin Oncol 2012; 30:1796-804
von Minckwitz Gunter, Mehta Keyur, Nekljudova Valentina, Denkert Carsten, Konecny Gottfried E, Kaufmann Manfred, Jackisch Christian, Huober Jens, Hilfrich Jörn, Eiermann Wolfgang, Gerber Bernd, Fasching Peter A, Eidtmann Holger, Costa Serban D, Blohmer Jens-Uwe, Untch Michael, Loibl Sibylle
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
von Minckwitz G, Blohmer J, Huober J, Hauschild M, Fehm T, Müller B, Denkert C, Loibl S, Nekljudova V, Untch M, German Breast Group, Kunz G, Jackisch C, Gerber B, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366:299-309.
26.01.2012Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
26.01.2012N Engl J Med 2012; 366:299-309
von Minckwitz Gunter, Blohmer Jens-Uwe, Huober Jens, Hauschild Maik, Fehm Tanja, Müller Berit Maria, Denkert Carsten, Loibl Sibylle, Nekljudova Valentina, Untch Michael, German Breast Group, Kunz Georg, Jackisch Christian, Gerber Bernd, Eidtmann Holger, Rezai Mahdi, Fasching Peter A, Tesch Hans, Eggemann Holm, Schrader Iris, Kittel Kornelia, Hanusch Claus, Kreienberg Rolf, Solbach Christine, Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Untch M, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G, German Breast Group (GBG), Hanusch C, Tesch H, Kreienberg R, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J, Hilfrich J, Strumberg D, Fasching P, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012; 13:135-44.
17.01.2012Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
17.01.2012Lancet Oncol 2012; 13:135-44
Untch Michael, Gerber Bernd, Rezai Mahdi, Jackisch Christian, Huober Jens, Kühn Thorsten, Nekljudova Valentina, von Minckwitz Gunter, German Breast Group (GBG), Hanusch Claus, Tesch Hans, Kreienberg Rolf, Loibl Sibylle, Bischoff Joachim, Eidtmann Holger, Kaufmann Manfred, Blohmer Jens-Uwe, Hilfrich Jörn, Strumberg Dirk, Fasching Peter A, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
von Minckwitz G, Untch M, Diebold K, Tiemann K, Hoffmann G, Henschen S, Schrader I, Hanusch C, Clemens M, Just M, Dietrich K, Eidtmann H, Holms F, Solbach C, Tesch H, Huober J, Loibl S, Darb-Esfahani S, Denkert C. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat 2011
12.06.2011Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
12.06.2011Breast Cancer Res Treat 2011
von Minckwitz Gunter, Untch Michael, Diebold Kurt, Tiemann Katharina, Hoffmann Gerald, Henschen Stephan, Schrader Iris, Hanusch Claus, Clemens Michael R, Just Marianne, Dietrich Klaus, Eidtmann Holger, Holms Frank, Solbach Christine, Tesch Hans, Huober Jens, Loibl Sibylle, Darb-Esfahani Silvia, Denkert Carsten
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
von Minckwitz G, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jackisch C, Hilfrich J, Mehta K, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching P, Eiermann W, Blohmer J, Costa S, Jüni P. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2010; 125:145-56.
03.11.2010Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
03.11.2010Breast Cancer Res Treat 2010; 125:145-56
von Minckwitz Gunter, Gerber Bernd, du Bois Andreas, Huober Jens, Hanusch Claus, Konecny Gottfried, Fett Werner, Stickeler Elmar, Harbeck Nadia, Müller Volkmar, Jackisch Christian, Hilfrich Jörn, Mehta Keyur, Untch Michael, Nüesch Eveline, Loibl Sibylle, Kaufmann Manfred, Kümmel Sherko, Fasching Peter A, Eiermann Wolfgang, Blohmer Jens-Uwe, Costa Serban Dan, Jüni Peter
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial
Witzel I, Untch M, Roller M, Eulenburg C, Barinoff J, Hilfrich J, Just M, Latos K, Tesch H, Lantzsch T, Hauschild M, Henschen S, Hanusch C, Huober J, Mundhenke C, von Minckwitz G, Loibl S, Müller V. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res Treat 2010; 123:437-45.
01.09.2010Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial
01.09.2010Breast Cancer Res Treat 2010; 123:437-45
Witzel Isabell, Untch Michael, Roller Marc, Eulenburg Christine Zu, Barinoff Jana, Hilfrich Jörn, Just Marianne, Latos Kunibert, Tesch Hans, Lantzsch Tilmann, Hauschild Maik, Henschen Stephan, Hanusch Claus, Huober Jens, Mundhenke Christoph, von Minckwitz Gunter, Loibl Sibylle, Müller Volkmar
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study
Moebus V, Konecny G, Kreienberg R, Hinke A, Runnebaum I, von Minckwitz G, Harbeck N, Huober J, Schneeweiss A, Nitz U, Kuhn W, Kurbacher C, Thomssen C, du Bois A, Lueck H, Jackisch C, Untch M. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010; 28:2874-80.
10.06.2010Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study
10.06.2010J Clin Oncol 2010; 28:2874-80
Moebus Volker, Konecny Gottfried E, Kreienberg Rolf, Hinke Axel, Runnebaum Ingo B, von Minckwitz Gunter, Harbeck Nadia, Huober Jens, Schneeweiss Andreas, Nitz Ulrike, Kuhn Walther, Kurbacher Christian, Thomssen Christoph, du Bois Andreas, Lueck Hans-Joachim, Jackisch Christian, Untch Michael
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
Riethdorf S, von Minckwitz G, Untch M, Eidtmann H, Tesch H, Holms F, Hilfrich J, Schrader I, Fehm T, Huober J, Roller M, Komor M, Loibl S, Rau T, Zhang L, Müller V, Pantel K. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16:2634-45.
20.04.2010Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
20.04.2010Clin Cancer Res 2010; 16:2634-45
Riethdorf Sabine, von Minckwitz Gunter, Untch Michael, Eidtmann Holger, Tesch Hans, Holms Frank, Hilfrich Jörn, Schrader Iris, Fehm Tanja, Huober Jens, Roller Marc, Komor Martina, Loibl Sibylle, Rau Thomas, Zhang Liling, Müller Volkmar, Pantel Klaus
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
von Minckwitz G, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Untch M. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010; 28:2015-23.
22.03.2010Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
22.03.2010J Clin Oncol 2010; 28:2015-23
von Minckwitz Gunter, Kühn Thorsten, du Bois Andreas, Blohmer Jens-Uwe, Thomssen Christoph, Dan Costa Serban, Jackisch Christian, Kaufmann Manfred, Mehta Keyur, Hanusch Claus, Gerber Bernd, Rezai Mahdi, Loibl Sibylle, Fasching Peter A, Huober Jens, Tesch Hans, Bauerfeind Ingo, Hilfrich Jörn, Eidtmann Holger, Untch Michael
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
Untch M, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, von Minckwitz G. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28:2024-31.
22.03.2010Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
22.03.2010J Clin Oncol 2010; 28:2024-31
Untch Michael, Kühn Thorsten, du Bois Andreas, Blohmer Jens-Uwe, Thomssen Christoph, Dan Costa Serban, Jackisch Christian, Kaufmann Manfred, Mehta Keyur, Hanusch Claus, Gerber Bernd, Rezai Mahdi, Loibl Sibylle, Fasching Peter A, Huober Jens, Tesch Hans, Bauerfeind Ingo, Hilfrich Jörn, Eidtmann Holger, von Minckwitz Gunter